(Q44471012)

3 December 2017

Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. (English)

1 reference

3 December 2017

0 references

1 reference

1

1 reference

3 December 2017

7

1 reference

3 December 2017

5

Jean Charles Piette

1 reference

3 December 2017

Vlad Ratziu

2

1 reference

3 December 2017

Robert P Myers

3

1 reference

3 December 2017

Pascale Ghillani

4

1 reference

3 December 2017

Joseph Moussalli

6

1 reference

3 December 2017

Multivirc Group

8

1 reference

3 December 2017

1 June 2002

1 reference

3 December 2017

Journal of Hepatology

1 reference

3 December 2017

36

1 reference

3 December 2017

6

1 reference

3 December 2017

812-818

1 reference

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Non-organ specific autoantibodies associated with chronic C virus hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Hepatitis C virus infection: quality of life and side effects of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Biologic and clinical significance of cryoglobulins. A report of 86 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Hepatitis C virus infection in type II mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

A French consensus conference on hepatitis C: screening and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Serum cytokine values and fatigue in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Evidence for a cerebral effect of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Chronic fatigue: symptom and syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Population based study of fatigue and psychological distress

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

A community-based study of chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Chronic fatigue in primary care attenders

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Cellular networks in hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900067-3

7 January 2021

10.1016/S0168-8278(02)00067-3

Identifiers

DOI

1 reference

3 December 2017

1 reference